ArriVent BioPharma, Inc. (AVBP)

NGM – Real Time Price. Currency in USD

34.00

+0.17 (0.52%)

At close: Jun 26, 2026, 4:00 PM EDT

34.00

-0.00 (-0.00%)

After-hours: Jun 26, 2026, 4:36 PM EDT

16.05.2026

ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case

Management reiterated that the move from early 2026 to mid-2026 was driven by slower event accumulation rather than operational issues, enrollment challenges, or trial redesign. ArriVent ended Q1 with $326.4 million of cash and extended its expected runway from Q3 2027 to Q4 2027, reducing near-term funding risk while supporting late-stage development and commercialization efforts. Shanghai Allist continues to demonstrate strong commercial momentum in China, while ARR-002 adds a new potential growth driver.

11.05.2026

ArriVent BioPharma Reports First Quarter 2026 Financial Results

NEWTOWN SQUARE, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent Company progress.

07.05.2026

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ARR-002, a potential first-in-class MUC16/NaPi2b targeting tetravalent antibody-drug conjugate (ADC) with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors.

15.04.2026

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investors? Let's find out.

06.04.2026

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

26.03.2026

Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?

Here is how ArriVent BioPharma, Inc. (AVBP) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

24.03.2026

ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib

The readout for Firmonertinib has moved to mid-2026, which may reflect slower event accumulation and potentially longer progression-free survival compared with the current standard of care. If the drug delivers PFS above ~10 months with statistical significance, Firmonertinib could capture meaningful market share thanks to its oral monotherapy profile and potentially better safety relative to Rybrevant. With $312 million cash (runway to Q3 2027), the valuation appears asymmetric relative. We remain buyers.

Videos

No Data

There is no data to display

Press releases

11.05.2026

ArriVent BioPharma Reports First Quarter 2026 Financial Results

07.05.2026

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

05.03.2026

ArriVent BioPharma Reports Full Year 2025 Financial Results

NEWTOWN SQUARE, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the year ended December 31, 2025, and highlighted recent Company progress.

22.12.2025

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

NEWTOWN SQUARE, Pa., Dec. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the first patient has been dosed in the global pivotal Phase 3 ALPACCA study evaluating firmonertinib monotherapy for first-line treatment of EGFR PACC mutant non-small cell lung cancer (NSCLC). Firmonertinib is an oral, once daily, highly brain-penetrant and broadly active mutation-selective EGFR inhibitor.

ArriVent BioPharma, Inc. (AVBP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case

ArriVent BioPharma Reports First Quarter 2026 Financial Results

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?

ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib

Videos

No Data

Press releases

ArriVent BioPharma Reports First Quarter 2026 Financial Results

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

ArriVent BioPharma Reports Full Year 2025 Financial Results

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case

ArriVent BioPharma Reports First Quarter 2026 Financial Results

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?

ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib

Videos

No Data

Press releases

ArriVent BioPharma Reports First Quarter 2026 Financial Results

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

ArriVent BioPharma Reports Full Year 2025 Financial Results

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

Search stocks

ArriVent BioPharma, Inc. (AVBP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case

ArriVent BioPharma Reports First Quarter 2026 Financial Results

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?

ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib

Videos

No Data

Press releases

ArriVent BioPharma Reports First Quarter 2026 Financial Results

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

ArriVent BioPharma Reports Full Year 2025 Financial Results

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case

ArriVent BioPharma Reports First Quarter 2026 Financial Results

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?

ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib

Videos

No Data

Press releases

ArriVent BioPharma Reports First Quarter 2026 Financial Results

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

ArriVent BioPharma Reports Full Year 2025 Financial Results

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer